ArQule Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
ArQule (ARQL) PT Raised to $9 at Needham & Company
May 1, 2019 11:28 AM EDTNeedham & Company analyst Chad Messer raised the price target on ArQule (NASDAQ: ARQL) to $9.00 (from $7.00) while maintaining a Buy rating.
The analyst commented, :ArQule is currently enrolling a 75 mg dose cohort (cohort 8) in the Phase I study of ARQ531. A... More
ArQule (ARQL) Misses Q1 EPS by 1c, Revenues Miss; Affirms 2Q EPS/Revenue Outlook
May 1, 2019 7:25 AM EDTArQule (NASDAQ: ARQL) reported Q1 EPS of ($0.09), $0.01 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $1.35 million versus the consensus estimate of $2.1 million.
Paolo Pucci, Chief Executive Officer of ArQule, commented, We have made tremendous progress across our... More
